Midatech is heavily committed to making treatment a reality for rare disease patients with crucial unmet need and has recently commenced dosing of its MTX110 treatment for diffuse intrinsic pontine glioma (DIPG), an ultra-rare and currently fatal childhood brain tumour, on a named patient basis through leading neuro-surgery and paediatric oncology practitioners in Bristol, a treatment for which compassionate use requests are rapidly emerging.
"One of the focus areas of our current development strategy is oncology and we are pleased to be able to announce that we have commenced dosing of our MTX110 treatment for DIPG, an ultra-rare childhood tumour, on International Rare Disease Day 2016,” said Dr Jim Phillips, chief executive officer of Midatech.
“We are committed to helping rare disease patients where there is a high unmet need, including those with the ultra-rare condition DIPG. The lack of treatment alternatives for this condition coupled with our recent clinical-use advances means we are optimistic about seeing a fast-tracked product reach the market in the near future for the benefit of these patients," he added.
Shares in Midatech fell 0.2% to 170.2p in the first hour of trading in a market that was off 0.9%.